Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IART Stock Forecast 2025-2026
$11.91
Current Price
$944.20M
Market Cap
Buy 3
Hold 5
Sell 4
Wall St Analyst Ratings
Distance to IART Price Targets
+151.9%
To High Target of $30.00
+13.4%
To Median Target of $13.50
-16.0%
To Low Target of $10.00
IART Price Momentum
-6.1%
1 Week Change
-12.1%
1 Month Change
-58.9%
1 Year Change
-47.5%
Year-to-Date Change
-63.5%
From 52W High of $32.66
+2.7%
From 52W Low of $11.60
📊 TOP ANALYST CALLS
Did IART Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Integra is one of their latest high-conviction picks.
Latest IART Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, IART has a neutral consensus with a median price target of $13.50 (ranging from $10.00 to $30.00). The overall analyst rating is Hold (5.8/10). Currently trading at $11.91, the median forecast implies a 13.4% upside. This outlook is supported by 3 Buy, 5 Hold, and 4 Sell ratings.
The most optimistic forecast comes from Joanne Wuensch at Citigroup, projecting a 151.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IART Analyst Ratings
3
Buy
5
Hold
4
Sell
IART Price Target Range
Low
$10.00
Average
$13.50
High
$30.00
Current: $11.91
Latest IART Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IART.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $25.00 |
| May 6, 2025 | JP Morgan | Robbie Marcus | Underweight | Maintains | $12.00 |
| May 6, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $13.00 |
| Apr 11, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $19.00 |
| Mar 31, 2025 | Argus Research | David Toung | Buy | Upgrade | $0.00 |
| Feb 26, 2025 | Citizens Capital Markets | David Turkaly | Market Outperform | Reiterates | $35.00 |
| Nov 5, 2024 | Citigroup | Joanne Wuensch | Sell | Maintains | $22.00 |
| Oct 14, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $21.00 |
| Oct 7, 2024 | B of A Securities | Craig Bijou | Underperform | Maintains | $18.00 |
| Oct 7, 2024 | BTIG | Ryan Zimmerman | Neutral | Upgrade | $0.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Sell | Maintains | $16.00 |
| Aug 28, 2024 | BTIG | Ryan Zimmerman | Sell | Maintains | $20.00 |
| Aug 22, 2024 | Citigroup | Joanne Wuensch | Sell | Maintains | $20.00 |
| Jul 30, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $26.00 |
| Jul 30, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $35.00 |
| Jul 30, 2024 | Citigroup | Joanne Wuensch | Sell | Downgrade | $23.00 |
| Jul 30, 2024 | BTIG | Ryan Zimmerman | Sell | Downgrade | $22.00 |
| Jul 16, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $32.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Underweight | Maintains | $27.00 |
| Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 |
Integra LifeSciences Holdings Corporation (IART) Competitors
The following stocks are similar to Integra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
IART
Integra LifeSciences
mkt cap
944.98M
Integra LifeSciences Holdings Corporation (IART) Financial Data
Integra LifeSciences Holdings Corporation has a market capitalization of $944.20M with a P/E ratio of 66.5x. The company generates $1.62B in trailing twelve-month revenue with a -1.8% profit margin.
Revenue growth is +3.7% quarter-over-quarter, while maintaining an operating margin of +8.2% and return on equity of -1.9%.
Valuation Metrics
Market Cap
$944.20M
Enterprise Value
$2.69B
P/E Ratio
66.5x
PEG Ratio
4.8x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
+3.7%
Gross Margin
+50.8%
Operating Margin
+8.2%
Net Margin
-1.8%
EPS Growth
+3.7%
Financial Health
Cash/Price Ratio
+29.5%
Current Ratio
1.2x
Debt/Equity
132.6x
ROE
-1.9%
ROA
+2.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Integra LifeSciences Holdings Corporation (IART) Business Model
About Integra LifeSciences Holdings Corporation
What They Do
Develops innovative medical devices for healthcare.
Business Model
Integra LifeSciences generates revenue by developing, manufacturing, and marketing a range of medical devices primarily used in neurosurgery, reconstructive surgery, and regenerative medicine. The company serves hospitals, surgical centers, and rehabilitation facilities, which rely on its products to improve surgical procedures and patient outcomes.
Additional Information
Founded in 1989, Integra LifeSciences has a strong presence in both domestic and international markets. The company is committed to advancing medical technology and enhancing patient care through ongoing research and development efforts.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
4,396
CEO
Ms. Mojdeh Poul
Country
United States
IPO Year
1995
Website
www.integralife.comIntegra LifeSciences Holdings Corporation (IART) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors of Integra LifeSciences Holdings Corporation (NASDAQ: IART). Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation by Pomerantz LLP may indicate potential legal issues for Integra LifeSciences, which could impact stock performance and investor sentiment negatively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Integra LifeSciences Holdings Corporation (NASDAQ: IART). Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation suggests potential legal issues for Integra LifeSciences, which may impact its stock price and investor confidence, leading to heightened volatility in the market.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Kaskela Law LLC is investigating potential fiduciary duty breaches by Integra LifeSciences (NASDAQ:IART) for long-term investors following a securities fraud complaint related to stock purchases from March 2019 to May 2023.
Why It Matters
The investigation into Integra LifeSciences for potential fiduciary breaches and securities fraud may signal legal risks, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Integra (IART) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for potential stock movements.
Why It Matters
Earnings reports can influence stock prices and investor sentiment. Analysts may adjust forecasts based on performance, impacting Integra's market perception and future valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Integra LifeSciences Holdings Corporation (NASDAQ:IART). Interested parties can visit bgandg.com/IART for details.
Why It Matters
The investigation into Integra LifeSciences may signal potential legal issues or financial instability, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Investors should monitor Integra LifeSciences stock due to recent activity in the options market.
Why It Matters
Increased activity in Integra LifeSciences' options market signals potential volatility or significant price movement, indicating changing investor sentiment and future stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About IART Stock
What is Integra LifeSciences Holdings Corporation's (IART) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Integra LifeSciences Holdings Corporation (IART) has a median price target of $13.50. The highest price target is $30.00 and the lowest is $10.00.
Is IART stock a good investment in 2025?
According to current analyst ratings, IART has 3 Buy ratings, 5 Hold ratings, and 4 Sell ratings. The stock is currently trading at $11.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IART stock?
Wall Street analysts predict IART stock could reach $13.50 in the next 12 months. This represents a 13.4% increase from the current price of $11.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Integra LifeSciences Holdings Corporation's business model?
Integra LifeSciences generates revenue by developing, manufacturing, and marketing a range of medical devices primarily used in neurosurgery, reconstructive surgery, and regenerative medicine. The company serves hospitals, surgical centers, and rehabilitation facilities, which rely on its products to improve surgical procedures and patient outcomes.
What is the highest forecasted price for IART Integra LifeSciences Holdings Corporation?
The highest price target for IART is $30.00 from Joanne Wuensch at Citigroup, which represents a 151.9% increase from the current price of $11.91.
What is the lowest forecasted price for IART Integra LifeSciences Holdings Corporation?
The lowest price target for IART is $10.00 from at , which represents a -16.0% decrease from the current price of $11.91.
What is the overall IART consensus from analysts for Integra LifeSciences Holdings Corporation?
The overall analyst consensus for IART is neutral. Out of 17 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 4 as Sell, with a median price target of $13.50.
How accurate are IART stock price projections?
Stock price projections, including those for Integra LifeSciences Holdings Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 5:18 AM UTC